Facebook
Twitter
LinkedIn
Forward
Modern and Collaborative Approaches to Dry Eye Disease Diagnosis, Treatment, and Management (CE Webcast)
Activity Description and Purpose
The number of people with dry eye disease (DED) is increasing, likely due to the influence of acts of modern living, such as use of digital screens and working in indoor office environments. The increase in DED prevalence is not age specific; both young and old patients are sitting in the chairs of eye care practitioners with signs and symptoms of DED. These patients are often first seen by optometrists, who are at the front line of eye health and work collaboratively with ophthalmologists on more severe cases of DED. This collaboration extends into the surgical room. A successful comanaging partnership between the optometrist and the ophthalmologist ensures that patients achieve and maintain a healthy ocular surface throughout the entire surgical process. The desired results of this activity are to update clinicians on diagnostic and treatment strategies for the management of DED as well as collaborative strategies that can better educate patients on their role in the successful management of their DED.
This continuing medical education activity is provided by MedEdicus LLC.
This continuing education activity is supported through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
Click below for a downloadable patient education brochure on dry eye disease:
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Recognize factors that influence the evolving prevalence of dry eye disease
- Select appropriate tests for diagnosing dry eye disease
- Describe the implications of inflammation in dry eye disease on treatment
- Select the most appropriate treatment regimen for individual patients with dry eye disease
- Incorporate education regularly into patient encounters
Faculty
 | Kendall E. Donaldson, MD, MS (Co-Chair) Professor of Clinical Ophthalmology Medical Director Bascom Palmer Eye Institute in Plantation Plantation, Florida |
 | Walter O. Whitley, OD, MBA, FAAO (Co-Chair) Director, Optometric Services Virginia Eye Consultants Virginia Beach, Virginia |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Kendall E. Donaldson, MD, MS, is a consultant for Alcon; Allergan; Bausch & Lomb Incorporated; Dompé US, Inc; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Lumenis; Omeros Corporation; TissueTech, Inc; and Zeiss.
Walter O. Whitley, OD, MBA, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos Corporation, Horizon Therapeutics plc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Notal Vision, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, OCuSOFT Inc, Oyster Point Pharma, Inc, Quidel Corporation, Regener-Eyes, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, and Thea Pharmaceuticals Limited; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Bausch & Lomb Incorporated, Bio-Tissue, Eyevance, Novartis Pharmaceuticals Corporation, ScienceBased Health, and Sun Pharmaceutical Industries, Inc; and has ownership interest in Leo Lens Technology, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 70853-AS (Enduring Distance Learning)
COPE Course Category: Treatment & Management of Ocular Disease: Anterior Segment (AS)
Administrator: 
Sponsored by: 
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Novartis Pharmaceuticals Corporation.
This CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 236
Available Credit
- 1.00 COPE
Clicking Register indicates that you have reviewed the CE information for this activity.
Learning Method and Medium
This educational activity consists of a six (6)-question pretest, a webcast, and four (4) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.0 hour to complete.